BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 18611975)

  • 21. Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes.
    Wiesli P; Krayenbühl P; Uthoff H; Seifert B; Schmid C
    Diabetologia; 2009 Sep; 52(9):1816-9. PubMed ID: 19565212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
    Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
    Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.
    McKeage K; Goa KL
    Treat Endocrinol; 2002; 1(1):55-8. PubMed ID: 15765621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Summaries for patients. A comparison of three insulin regimens (morning glargine, bedtime glargine, or bedtime neutral protamine Hagedorn) in addition to a pill for treating type 2 diabetes.
    Ann Intern Med; 2003 Jun; 138(12):I33. PubMed ID: 12809480
    [No Abstract]   [Full Text] [Related]  

  • 25. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
    Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
    Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients.
    Hsia SH
    Diabetes Res Clin Pract; 2011 Mar; 91(3):293-9. PubMed ID: 21146881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
    J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.
    Home PD; Rosskamp R; Forjanic-Klapproth J; Dressler A;
    Diabetes Metab Res Rev; 2005; 21(6):545-53. PubMed ID: 16021649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
    Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
    Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
    Scholtz HE; Pretorius SG; Wessels DH; Becker RH
    Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes].
    Mianowska B; Szadkowska A; Czerniawska E; Pietrzak I; Bodalski J
    Pediatr Endocrinol Diabetes Metab; 2007; 13(4):189-93. PubMed ID: 18042313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
    Duckworth W; Davis SN
    J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
    Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
    Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
    Yeldandi RR; Lurie A; Baldwin D
    Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system.
    Wang XL; Lu JM; Pan CY; Mu YM; Dou JT; Ba JM; Wang X
    Diabetes Res Clin Pract; 2007 Apr; 76(1):30-6. PubMed ID: 16979255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients.
    HOE 901/2004 Study Investigators Group
    Diabet Med; 2003 Jul; 20(7):545-51. PubMed ID: 12823235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].
    Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S
    Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
    Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
    Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study.
    Zdarska DJ; Kvapil M; Rusavy Z; Krcma M; Broz J; Krivska B; Kadlecova P
    Wien Klin Wochenschr; 2014 Apr; 126(7-8):228-37. PubMed ID: 24563017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.